Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary
for their growth. Monoclonal antibodies such as rituximab can locate cancer cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Giving
bortezomib together with rituximab may kill more cancer cells.
PURPOSE: This randomized phase II trial is studying how well giving bortezomib together with
rituximab works in treating patients with relapsed or refractory non-Hodgkin's lymphoma.